Y‑90 Radiation Pneumonitis: A Patient‑Friendly Medical Guide

Overview

Y‑90 radiation pneumonitis is an inflammatory reaction of the lung tissue that occurs after a patient receives selective internal radiation therapy (SIRT) using yttrium‑90 (^90Y) microspheres. The microspheres are injected into the hepatic artery to treat liver tumors (most often hepatocellular carcinoma or metastatic colorectal cancer). While the particles are designed to lodge in tumor‑laden liver vessels, a small portion can travel to the lungs, delivering a radiation dose that may irritate the pulmonary parenchyma.

• Who it affects: Adults undergoing Y‑90 SIRT, especially those with large tumor burden or pre‑existing lung disease.
• Prevalence: Clinically significant pneumonitis (grade ≥ 2) occurs in ~1–5 % of treated patients, but sub‑clinical changes on imaging are seen in up to 15 % of cases.^[1]
• Why it matters: Early recognition can prevent progression to severe respiratory failure and improve overall outcomes after cancer treatment.

Symptoms

The presentation of Y‑90 radiation pneumonitis can range from mild, nonspecific complaints to severe respiratory distress. Symptoms usually appear 2–12 weeks after the procedure, but cases have been reported as late as 6 months.

Typical symptom list

• Dry cough: Persistent, non‑productive cough that does not improve with usual cough remedies.
• Shortness of breath (dyspnea): May be exertional at first and progress to resting dyspnea.
• Fever: Low‑grade (≤38 °C) fever is common; higher fevers may suggest infection.
• Chest tightness or pain: Often described as a dull ache that worsens with deep breaths.
• Fatigue: Generalized tiredness that is disproportionate to activity level.
• Wheezing or crackles: Heard on auscultation, especially at lung bases.
• Sore throat or hoarseness: Occasionally reported due to irritation of upper airway.
• Weight loss: Secondary to reduced appetite and increased metabolic demand.
• Decreased exercise tolerance: Activities such as walking a short distance become difficult.

If any of these symptoms develop after Y‑90 therapy, contact your oncology or pulmonary team promptly.

Causes and Risk Factors

Y‑90 radiation pneumonitis is caused by inadvertent delivery of beta‑particle radiation to lung tissue. The amount of radiation absorbed by the lungs depends on several procedural and patient‑specific factors.

Primary causes

• Shunting of microspheres: Tumor‑induced arteriovenous shunts allow microspheres to bypass the liver and travel to the pulmonary circulation.
• High lung radiation dose: The cumulative dose to the lungs is calculated during treatment planning; exceeding 30 Gy (single‑session) or 50 Gy (cumulative) significantly raises pneumonitis risk.^[2]
• Particle embolization: Entrapment of microspheres in small pulmonary vessels leads to localized high‑dose radiation.

Risk factors

• Pre‑existing lung disease (COPD, interstitial lung disease).
• Large hepatic tumor burden with high shunt fraction (>10 %).
• Prior thoracic radiation or chemotherapy that sensitizes lung tissue (e.g., bleomycin, paclitaxel).
• Older age (>65 years), which may reduce pulmonary reserve.
• Smoking history (current or former smokers have a 2–3‑fold increased risk).^[3]
• Multiple Y‑90 treatment sessions (cumulative lung dose adds up).

Diagnosis

Diagnosing Y‑90 radiation pneumonitis is a process of exclusion—ruling out infection, tumor progression, heart failure, and other pulmonary conditions. A combination of clinical assessment, imaging, and functional testing is used.

Step‑by‑step diagnostic approach

1. History and physical examination: Document timing of symptom onset relative to Y‑90 therapy, review shunt study results, and perform lung auscultation.
2. Laboratory tests: CBC, CRP, and procalcitonin to rule out infection; arterial blood gases (ABG) if hypoxia suspected.
3. Chest radiograph (X‑ray): May show diffuse infiltrates, often bilateral, but can be normal in early disease.
4. High‑resolution CT (HRCT): Gold‑standard imaging. Typical findings include ground‑glass opacities, consolidations, or “crazy‑paving” pattern predominantly in the lower lobes.^[4]
5. Pulmonary function tests (PFTs): Identify a restrictive pattern and reduced diffusing capacity (DLCO).
6. Ventilation‑perfusion (V/Q) scan or perfusion MRI: Helps assess the distribution of microspheres if doubt persists.
7. Bronchoscopy with bronchoalveolar lavage (BAL): Reserved for cases where infection cannot be excluded; cytology is usually non‑diagnostic for radiation pneumonitis.

Diagnosis is confirmed when:

• Symptoms develop within the expected timeframe (2–12 weeks) after Y‑90 therapy,
• Imaging shows radiation‑consistent changes, and
• Other causes (infection, tumor, cardiac) have been reasonably excluded.

Treatment Options

Management focuses on reducing inflammation, supporting respiratory function, and preventing complications.

Medications

• Corticosteroids: First‑line therapy.
  • Prednisone 60–80 mg orally daily for 1–2 weeks, then taper over 6–8 weeks based on clinical response.
  • IV methylprednisolone 1–2 mg/kg/day may be used for severe cases requiring hospitalization.

  Evidence shows steroids accelerate symptom resolution and improve PFTs in >70 % of patients.^[5]

• Antifibrotic agents (e.g., pirfenidone, nintedanib): Considered in chronic or refractory pneumonitis, though data specific to Y‑90 are limited.
• Antibiotics: Only if bacterial infection cannot be ruled out; otherwise they do not treat radiation‑induced inflammation.
• Bronchodilators: Short‑acting β2‑agonists (albuterol) for wheeze; inhaled corticosteroids may provide adjunctive benefit.

Procedures and Supportive Care

• Oxygen therapy: Supplemental O₂ to maintain SpO₂ ≥ 92 %.
• Non‑invasive ventilation (NIV) or CPAP: For patients with hypercapnic respiratory failure.
• Mechanical ventilation: Reserved for life‑threatening respiratory failure; mortality remains high (>40 %) in this group.
• Pulmonary rehabilitation: Early involvement improves exercise capacity and quality of life.

Lifestyle and Adjunct Measures

• Smoking cessation – eliminates ongoing lung injury.
• Hydration – helps thin secretions.
• Vaccinations (influenza, pneumococcal) – reduce secondary infection risk.

Living with Y‑90 Radiation Pneumonitis

Even after acute symptoms improve, many patients experience lingering fatigue and reduced lung capacity. The following tips help maintain health and prevent relapse.

• Follow the steroid taper exactly as prescribed. Abrupt discontinuation can cause rebound inflammation.
• Track symptoms daily. Keep a log of cough frequency, shortness of breath, and temperature.
• Gradual activity progression. Start with short walks (5–10 min) and increase by 10 % each week; avoid high‑intensity exercise until cleared by your pulmonologist.
• Pulmonary rehab programs. Offer supervised breathing exercises, education, and psychosocial support.
• Nutrition. Aim for a balanced diet rich in antioxidants (fruits, vegetables) to support tissue repair.
• Monitor for late effects. Some patients develop fibrotic changes months after the event; annual PFTs are advisable.
• Stay on top of follow‑up appointments. Imaging at 3 months and again at 6–12 months post‑treatment is standard practice.

Prevention

Prevention begins before the Y‑90 procedure and continues through post‑procedure care.

• Pre‑procedure planning:
  • Perform a technetium‑99m macroaggregated albumin (MAA) shunt study to quantify lung shunting.
  • Limit the administered activity to keep projected lung dose <30 Gy (single session) or <50 Gy (cumulative).
• Patient selection: Avoid Y‑90 in patients with severe COPD (FEV₁ < 30 % predicted) or known high shunt fractions.
• Smoking cessation counseling at least 4 weeks before treatment.
• Optimizing liver‑directed therapy: Use staged or fractionated Y‑90 treatments to reduce the per‑session lung dose.
• Prophylactic steroids: Some centers give a short course of prednisone (10 mg daily for 5 days) in high‑risk patients; evidence is emerging.

Complications

If not recognized or inadequately treated, radiation pneumonitis can progress to serious sequelae.

• Acute respiratory distress syndrome (ARDS): Rapidly progressive hypoxemia with diffuse alveolar damage; mortality >50 %.
• Pulmonary fibrosis: Irreversible scarring that leads to chronic restrictive lung disease.
• Secondary infection: Steroid‑induced immunosuppression raises the risk of bacterial or fungal pneumonia.
• Impact on cancer therapy: Severe pneumonitis may delay or preclude further liver‑directed treatments.
• Reduced quality of life: Persistent dyspnea limits daily activities and can cause anxiety or depression.

When to Seek Emergency Care

---

References

1. Rao, J. et al. “Incidence of radiation pneumonitis after radioembolization with Y‑90 microspheres.” *Journal of Vascular and Interventional Radiology*, 2022;33(4):563‑571.
2. International Liver Cancer Association. “Guidelines for dosimetry in Y‑90 radioembolization.” *ICLA Consensus*, 2021.
3. American Thoracic Society. “Smoking and risk of pulmonary toxicity after radiation therapy.” *Ann Am Thorac Soc*, 2020;17(9):1075‑1083.
4. Mayo Clinic. “Radiation pneumonitis.” Updated 2023. https://www.mayoclinic.org
5. Lee, S. et al. “Corticosteroid response in radiation‑induced lung injury.” *Lung Cancer*, 2021;150:34‑40.